My understanding is that the subgroup where SLS-005 performed...

My understanding is that the subgroup where SLS-005 performed better was the group that had not been previously treated with Relyvrio. Is it possibly therefore that this group is ALSO the patients which have been more recently diagnosed with MND? i.e. they have not had MND long enough to have been put on Relyvrio and thus have suffered less nerve damage before going on the drug? We have already discussed on HC how the likelihood of MPL having a greater positive effect would be on a patient group which were newly diagnosed (maybe younger too?) Our current ALSFRS-R score is already better than that of the SLS-005 drug on their best performing subgroup (although admittedly on a very small number of patients). I wonder if we have even more room to widen that gap?